Poor
Not Aligned
Patient Risk:
High
Summary
Several dosing/administration claims are contradicted or not label-verified, including at least one high-severity incorrect combination regimen (HCC and esophageal cancer with ipilimumab). Multiple other statements are overgeneralized beyond label-specific stopping rules and/or not supported by the provided label excerpts.
Category Scores
Accurate Statements
Nivolumab is typically infused every 2 weeks (q2w) or every 4 weeks (q4w).
2.2 Recommended Dosage (Table 1): 240 mg every 2 weeks or 480 mg every 4 weeks
For melanoma, NSCLC, RCC, or MSI-H/dMMR tumors receiving nivolumab monotherapy, nivolumab is given as 240 mg every 2 weeks or 480 mg every 4 weeks until disease progression or unacceptable toxicity.
2.2 Recommended Dosage (Table 1): relevant single-agent indications list 240 mg q2w or 480 mg q4w with duration 'Until disease progression or unacceptable toxicity'
Nivolumab treatment may involve dose delays for toxicity management per protocol.
2.3 Dosage Modifications: 'In general, withhold OPDIVO...' for immune-mediated adverse reactions (withholding implies interruptions/delays)
Dose reductions aren't standard for nivolumab; instead, nivolumab is held or discontinued for adverse events like immune-related toxicities.
2.3 Dosage Modifications: 'No dose reduction for OPDIVO is recommended... withhold... permanently discontinue'
Unsupported Statements
For most approved adult uses, nivolumab is administered intravenously over 30 minutes.
2.2 states to administer OPDIVO as a 30-minute intravenous infusion for the provided general statement, but the response frames this as universal/'for most approved adult uses'; the provided label excerpt does not support that degree of generalization across all regimens/indications.
For most approved adult uses, nivolumab doses range from 240 mg q2w to 480 mg q4w.
The label excerpt includes multiple combination regimens and/or weight-based regimens (e.g., 360 mg every 3 weeks combinations; other regimens in Table 2; pediatric mg/kg in Table 1), so the 'most approved adult uses' framing is not supported by the provided label.
A treatment cycle aligns with the nivolumab infusion interval (e.g., 14 days for q2w or 28 days for q4w).
The label provides dosing intervals ('every 2 weeks' / 'every 4 weeks') but does not define 'treatment cycle' as 14/28 days.
Nivolumab treatment continues until disease progression.
Label durations for some regimens include additional stopping criteria such as 'unacceptable toxicity' and/or fixed-duration conditions (e.g., 'up to 2 years' or 'up to 1 year'), so the response omits material stopping-rule qualifiers.
Premedication is not required for nivolumab.
The provided label sections do not state that premedication is not required.
Monitoring for infusion reactions is routine with nivolumab.
The label excerpt supports specific management actions for infusion-related reactions (interrupt/slow or discontinue) and general monitoring for immune-mediated adverse reactions, but does not explicitly state that infusion-reaction monitoring is 'routine.'
Contradictions
Low
AI Statement
For malignant pleural mesothelioma with ipilimumab, nivolumab is given as 360 mg every 3 weeks for up to 2 years.
Label Reference
2.2 Recommended Dosage (Table 2): duration is 'until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression' (not 'for up to 2 years' without the 'without disease progression' condition)
High
AI Statement
For HCC or esophageal cancer with ipilimumab, nivolumab is given as 240 mg every 2 weeks in combination with ipilimumab 1 mg/kg every 6 weeks.
Label Reference
2.2 Recommended Dosage (Table 2): HCC with ipilimumab is '1 mg/kg every 3 weeks with ipilimumab 3 mg/kg' for combination; esophageal SCC with ipilimumab includes either '240 mg q2w/480 mg q4w with chemotherapy' or '3 mg/kg every 2 weeks or 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks' (not 240 mg q2w with ipilimumab 1 mg/kg q6w as stated)
Low
AI Statement
For urothelial carcinoma, nivolumab is given as 360 mg every 3 weeks with other agents.
Label Reference
2.2 Recommended Dosage (Table 2): first-line unresectable/metastatic urothelial carcinoma shows 360 mg every 3 weeks with cisplatin and gemcitabine for up to 6 cycles, but the claim is phrased without specifying the regimen context/duration and conflicts with the provided label's other urothelial carcinoma single-agent dosing (Table 1) and requires regimen specificity; as written, it is not label-precise.
Low
AI Statement
For most approved adult uses, nivolumab is administered intravenously over 30 minutes.
Label Reference
2.2 Recommended Dosage: includes the instruction 'Administer OPDIVO as a 30-minute intravenous infusion' but does not explicitly support the response’s 'for most approved adult uses' universal framing across all regimens.
Important Omissions
Boxed warnings, contraindications, and key safety statements for specific populations (e.g., pregnancy/lactation; pediatric considerations) are not evaluated/provided in the AI response excerpt and are not addressed here.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
An incorrect combination dosing regimen is explicitly contradicted in the provided label excerpt (HCC/esophageal SCC with ipilimumab), and multiple other dosing/duration/generalization statements are not label-verified. These issues could materially affect dosing schedule and treatment duration.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Contradicted and inaccurate combination dosing instructions (especially HCC/esophageal cancer with ipilimumab) plus overgeneralized stopping and administration statements not precisely supported by label language.
Suggested Improvement
Replace incorrect regimen details with the label-specific Table 2 dosing and duration conditions (including 'up to 2 years in patients without disease progression' where applicable), and qualify statements to match label stopping criteria ('until disease progression or unacceptable toxicity' and regimen-specific fixed-duration limits). Remove or revise claims not explicitly supported in the provided label excerpts (e.g., premedication not required; 'routine' infusion-reaction monitoring).